ALKS - The Bottom Fishing Club: Alkermes Has Great Value And Safety

2024-05-17 08:27:04 ET

Summary

• Alkermes is positioned for outperformance in the pharmaceutical sector due to its conservative cash-heavy balance sheet and high-margin business model.
• The company focuses on therapies for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and neurological disorders like narcolepsy.
• Alkermes has a very low valuation compared to peers in the pharmaceutical industry, making it an interesting pick to add defensive characteristics to your portfolio.

I have been concentrating my research on the pharmaceutical sector of the market over the last several weeks. I just posted my reiteration of the solid bullish arguments for owning Pfizer ( PFE ) here . A large number of prescription-drug names appear to be an inflection point, where defensive, safety-minded capital has been flowing. My technical momentum work suggests a major turn higher could be at hand for the industry, after several years of punk to lower performance....

For further details see: